The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.

Tag:

Pfizer

Latest Headlines

Latest Headlines

Pfizer gets access to more production capacity in Saudi Arabia with Tabuk deal

Pfizer has a manufacturing plant underway in Saudi Arabia that is slated to be operating next year. But the drugmaker has just struck a deal that will give it access to additional capacity, as well as products, in that country.

J&J, Pfizer in tug-of-war over ads for Infants' Advil

Back in 1989, a court order limited advertising claims for Advil, now owned by Pfizer. But does that order extend to Infants' Advil, which didn't exist at the time? Rival Johnson & Johnson says yes--and it's forced Pfizer to pull one of its ads for that very reason.

Prevnar use in seniors is cost-effective now, CDC says. But will it last?

After meeting to discuss the use of Pfizer's Prevnar 13 in adults 65 and older late last week, a CDC advisory committee isn't planning to vote on recommendation of the shot just yet. But when it does, it will have a few things to consider--including Prevnar's long-term cost effectiveness in that population--before giving it a nod.

Pfizer to partner with South African university on preclinical research

The partnership may include the use of Pfizer's genetically modified animal models to evaluate the safety and efficacy of therapeutic molecules in oncology, inflammation, immunology, central nervous system and cardiovascular system disorders.

Another Pfizer bid for AstraZeneca? Investors weigh in

A higher price could get a deal done between Pfizer and AstraZeneca if British regulators play along, but investors aren't convinced that would be a particularly good outcome for either company. The two pharmas aren't far apart on price, and any renewal of negotiations could come as early as August.

With Shire takeover bid, AbbVie looks to succeed where Pfizer failed

AbbVie may be working with some of the same advisers who worked on Pfizer's so-far-failed play for AstraZeneca. But after three rejections from target Shire--the latest totaling about $46.5 billion--it's not about to make Pfizer's same mistakes.

Eliquis scores DVT/PE recommendation in Europe

Right now, Eliquis, the new-age clot-fighter from Pfizer and Bristol-Myers Squibb, is in third place in a three-horse race. But as it tries to catch up to rivals Pradaxa and Xarelto--not to mention the $3-billion-per-year sales forecasts analysts slapped on it in its early days--a new recommendation for expanded use in Europe should give it a boost.

The top 5 vaccines by 2020

Take a look and at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013.

Pfizer buys big into CAR-T with sweeping Cellectis deal

Pfizer wants in on CAR-T technology, the latest much-celebrated trend in cancer R&D, striking a deal with France's Cellectis to get its hands on some tailored immunotherapies with the promise of billions in future payments.

Pfizer, Novartis square off for tussle in meningitis vaccine market

Pfizer and Novartis have been racing to get their meningitis B vaccines to market for years. But as of Tuesday, the contest has never been closer, with both companies submitting approval applications to the FDA. Now, it's up to the agency to decide which shot gets the green light first--and first crack at the wide-open patient pool that comes with it.